POZEN reports positive results from Phase III trials of PA32540
The randomized, double-blind, multi-center studies were randomly assigned to treatment with either PA32540 or 325mg enteric-coated aspirin once daily. The primary endpoint, a significant reduction in the cumulative
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.